TY - JOUR
T1 - Engineered macrophages acting as a trigger to induce inflammation only in tumor tissues
AU - Tanito, Kenta
AU - Nii, Teruki
AU - Yokoyama, Yuta
AU - Oishi, Haruka
AU - Shibata, Mayuka
AU - Hijii, Shoichi
AU - Kaneko, Ryosuke
AU - Tateishi, Chuya
AU - Ito, Shoko
AU - Kishimura, Akihiro
AU - Mori, Takeshi
AU - Katayama, Yoshiki
N1 - Publisher Copyright:
© 2023
PY - 2023/9
Y1 - 2023/9
N2 - Herein, we report engineered macrophages, termed “MacTrigger,” acting as a trigger to induce an inflammatory environment only in tumor tissues. This led to intensive anti-tumor effects based on the removal potential of foreign substances. The strength of this study is the utilization of two unique functions of macrophages: (1) their ability to migrate to tumor tissues and (2) polarization into the anti-inflammatory M2 phenotype in the presence of tumor tissues. The MacTrigger accelerated the release of inflammatory cytokines, tumor necrosis factor-alpha (TNF-α), when it was polarized to the M2 phenotype. When the MacTrigger was administered to tumor-bearing mice, tumor growth was significantly inhibited compared with the non-treatment group, the un-transfected macrophages group, and the group with engineered macrophages capable of randomly releasing TNF-α. Additionally, the ratio of the M1 phenotype to the M2 phenotype in tumor tissues was >1 only in the MacTrigger group. Moreover, the ratios of natural killer cells and CD8+T cells in tumor tissues were increased compared with other groups. These results indicate that MacTrigger can induce inflammation in tumor tissues, leading to effective anti-tumor effects. In normal tissues, especially the liver, notable side effects were not observed. This is because, in the liver, the MacTrigger was not polarized to the M2 phenotype and could not induce inflammation. These results suggest that the MacTrigger is a “trigger” that can induce inflammation only in tumor tissues, then allowing the body to attack tumor tissues through the innate immunity system.
AB - Herein, we report engineered macrophages, termed “MacTrigger,” acting as a trigger to induce an inflammatory environment only in tumor tissues. This led to intensive anti-tumor effects based on the removal potential of foreign substances. The strength of this study is the utilization of two unique functions of macrophages: (1) their ability to migrate to tumor tissues and (2) polarization into the anti-inflammatory M2 phenotype in the presence of tumor tissues. The MacTrigger accelerated the release of inflammatory cytokines, tumor necrosis factor-alpha (TNF-α), when it was polarized to the M2 phenotype. When the MacTrigger was administered to tumor-bearing mice, tumor growth was significantly inhibited compared with the non-treatment group, the un-transfected macrophages group, and the group with engineered macrophages capable of randomly releasing TNF-α. Additionally, the ratio of the M1 phenotype to the M2 phenotype in tumor tissues was >1 only in the MacTrigger group. Moreover, the ratios of natural killer cells and CD8+T cells in tumor tissues were increased compared with other groups. These results indicate that MacTrigger can induce inflammation in tumor tissues, leading to effective anti-tumor effects. In normal tissues, especially the liver, notable side effects were not observed. This is because, in the liver, the MacTrigger was not polarized to the M2 phenotype and could not induce inflammation. These results suggest that the MacTrigger is a “trigger” that can induce inflammation only in tumor tissues, then allowing the body to attack tumor tissues through the innate immunity system.
KW - Arginase 1
KW - Cell medicine
KW - Inflammation induction
KW - Macrophage
KW - Removal potential of foreign substances
KW - Tumor necrosis factor-α
UR - http://www.scopus.com/inward/record.url?scp=85158816288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85158816288&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2023.04.010
DO - 10.1016/j.jconrel.2023.04.010
M3 - Article
C2 - 37080897
AN - SCOPUS:85158816288
SN - 0168-3659
VL - 361
SP - 885
EP - 895
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -